Next Article in Journal
Liposomes Co-Encapsulating Cisplatin/Mifepristone Improve the Effect on Cervical Cancer: In Vitro and In Vivo Assessment
Next Article in Special Issue
Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations
Previous Article in Journal
Efficient Non-Viral Gene Modification of Mesenchymal Stromal Cells from Umbilical Cord Wharton’s Jelly with Polyethylenimine
Previous Article in Special Issue
Can Implementation of Genetics and Pharmacogenomics Improve Treatment of Chronic Low Back Pain?
Article

Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation

1
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Antioquia, Medellin 050010, Colombia
2
Liver Transplant Service, J.P. Garrahan Hospital, Buenos Aires C1245AAM, Argentina
3
Pathology Service, J.P. Garrahan Hospital, Buenos Aires C1245AAM, Argentina
4
Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires C1113, Argentina
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(9), 898; https://doi.org/10.3390/pharmaceutics12090898
Received: 11 December 2018 / Revised: 8 February 2019 / Accepted: 16 April 2019 / Published: 22 September 2020
The evidence available in the pediatric population is limited for making clinical decisions regarding the optimization of tacrolimus (TAC) in pharmacotherapy. The objective of this study was to estimate the frequency of CYP3A5 genetic polymorphisms and their relationship with tacrolimus requirements in the pediatric population. This was a longitudinal cohort study with a two-year follow-up of 77 patients under 18 years old who underwent a liver transplant during the period 2009–2012 at the J.P. Garrahan Pediatric Hospital. Tacrolimus levels from day five up to two years after the transplant were obtained from hospital records of routine therapeutic drug monitoring. The genotyping of CYP3A5 (CYP3A5*1/*3 or *3/*3) was performed in liver biopsies from both the donor and the recipient. The frequency of CYP3A5*1 expression for recipients was 37.1% and 32.2% for donors. Patients who received an expresser organ showed lower Co/dose, especially following 90 days after the surgery. The role of each polymorphism is different according to the number of days after the transplant, and it must be taken into account to optimize the benefits of TAC therapy during the post-transplant induction and maintenance phases. View Full-Text
Keywords: tacrolimus; CYP3A5; liver transplant; pharmacokinetics tacrolimus; CYP3A5; liver transplant; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Buendía, J.A.; Halac, E.; Bosaleh, A.; Garcia de Davila, M.T.; Imvertasa, O.; Bramuglia, G. Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. Pharmaceutics 2020, 12, 898. https://doi.org/10.3390/pharmaceutics12090898

AMA Style

Buendía JA, Halac E, Bosaleh A, Garcia de Davila MT, Imvertasa O, Bramuglia G. Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation. Pharmaceutics. 2020; 12(9):898. https://doi.org/10.3390/pharmaceutics12090898

Chicago/Turabian Style

Buendía, Jefferson A., Esteban Halac, Andrea Bosaleh, María T. Garcia de Davila, Oscar Imvertasa, and Guillermo Bramuglia. 2020. "Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation" Pharmaceutics 12, no. 9: 898. https://doi.org/10.3390/pharmaceutics12090898

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop